Inve India ▾

Influx Healthtech share price & results

Influx Healthtech Limited· Healthcare

Results to
Mar 2026
Latest analysed call
Q4 FY26
Ownership as of
Sept 2026

Palghar (Maharashtra)-based CDMO manufacturing nutraceuticals, cosmetics, ayurvedic/herbal formulations, veterinary feed supplements and homecare products for third-party brands.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue80.0 ₹ crore+40.4% YoYQuarterly, as filedQuarter to Mar 2026Revenue from operations as filed.
Operating margin19.0 %−1.0 pts YoYOperating profit / revenueQuarter to Mar 2026For the quarter; a change is in percentage points.
Net profit11.0 ₹ crore+37.5% YoYQuarterly, as filedQuarter to Mar 2026Profit after tax as filed.
Return on equityUnavailable—Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.
Free cash flow margin-13.99 %—Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)Unavailable—Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Mar 2026

Guidance

What management said, and what became of it

1 of 3 judged targets kept · 10 open · verdicts reflect calls analysed to Q4 FY26.

Influx Healthtech Limited management guidance track record on Inve: 13 targets tracked across analysed earnings calls (1 achieved, 2 missed, 10 open).

TargetOriginal wordingSaidLatest callVerdict
Regulatory ApprovalsTanzania audit on Dec 11
Call transcript, Q2 FY26 · 12 Nov 2025		Q2 FY26Q4 FY26:Management confirmed in the detailed narrative that 'regulatory approvals secured in Tanzania and Nigeria', successfully completing this objective.
Call transcript, Q4 FY26 · 22 May 2026		Achieved
RevenueINR 150+ crores in FY26
Call transcript, Q2 FY26 · 12 Nov 2025		Q2 FY26Q4 FY26:Company reported full-year FY26 revenue of INR 146 crores, slightly missing the guided target of INR 150+ crores.
Call transcript, Q4 FY26 · 22 May 2026		Missed
RevenueDouble the business by FY27
Call transcript, Q2 FY26 · 12 Nov 2025		Q2 FY26Q4 FY26:FY26 revenue closed at INR 146 Cr. Management's FY27 growth guidance of 25-30% (to ~INR 183-190 Cr) is not on a trajectory to double the FY25 base (~INR 105 Cr) by FY27.
Call transcript, Q4 FY26 · 22 May 2026		At Risk

Source: Inve Guidance Tracker for Influx Healthtech Limited · to Q4 FY26

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Influx Healthtech Limited's 13 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 10 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹253.85 −1.32% · −₹3.4

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +49.1% 1Y

₹200₹250₹300Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 12 Nov 2025Q4 FY26 — 22 May 2026

1Y: ₹170.25 on 24 Oct 2025 → ₹253.85. High ₹312.35 (6 Jul 2026), low ₹170.25 (24 Oct 2025).

Previous close
₹257.25
Market cap
₹602 Cr
52-week range
₹172.25 – ₹312.35
One year
+47.37%
Price to earnings (FY ending Mar 2026)
30.75×
Return on equity (FY ending Mar 2026)
19.39%

Overview

Symbol
NSE:INFLUX
Exchange
NSE
Currency
INR

What Influx Healthtech Limited does

Based on the company's own presentations, annual report and earnings calls.

Influx Healthtech is a contract development and manufacturing organisation (CDMO) that develops and manufactures dietary/nutritional supplements, cosmetics, ayurvedic/herbal formulations, veterinary feed supplements and homecare products on behalf of client brands. It runs an end-to-end model spanning formulation development, manufacturing and regulatory support, allowing clients (multinationals, D2C brands and niche healthcare providers) to focus on their own product discovery and commercialisation. Manufacturing is carried out across facilities in Palghar, Maharashtra, and the company also exports its products, having secured regulatory clearances in additional international markets such as Tanzania.

Segments

  • Nutraceuticals
  • Cosmetics
  • Ayurvedic/Herbal
  • Veterinary feed & pet care
  • Homecare
Manufacturing units
4 (Palghar, Maharashtra; 1 of the 4 facilities is rented)
Product range
3,428
Client base
718 clients
Client retention rate
98%
Export countries
36
Capacity utilization
70% (blended, FY26)
Founded 2020Headquarters Mumbai, Maharashtra, IndiaEmployees 160 (FY26) Company website

How the price took the results

close before → close after

Q4 FY26
+7.1%
22 May
Q2 FY26
+5.0%
12 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Influx Healthtech Limited

Free account: one company. Everything above stays public.

Write why you follow Influx Healthtech Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Influx Healthtech Limited

Guides on how to read this kind of business and the numbers that matter.